live News:
23andMe must secure its DNA databases immediately - 23andMe CEO reveals plans for the company's future - Inside 23andMe CEO Anne Wojcicki's vision for the company: It "will transform health care" - 23andMe CEO discusses rebuilding trust - 23andMe CEO on company's future amid financial struggles, data security incident - 23andMe is ending its cancer research program and slashing over 200 jobs - Tech layoffs update: AMD, iRobot, 23andMe, and other big firms see job losses in November 2024 - Victims of 23andMe's Data Breach Could Get $10,000. Here's What You Need to Know - 23andMe reports sales decline a day after announcing plans to cut 40% of workforce - 23andMe Lays Off 40% of Staff, Shuts Drug Development Business

23andMe

12 days ago
bookmarkBookmark

Key facts

Classified as: organization

Summary

23andMe is a company. It is located in South San Francisco, the United States and was founded in 2006. The company is part of the Health Care sector, specifically in the Health Care Providers & Services industry.

Business

  • Assets: 1.2B $
  • Debt: 86.3M $
  • Employees: get premium Premium to see estimate
  • Free cash flow: -64259600 $
  • Market cap: 1.6B $
  • Profits: -217490000 $
  • Revenues: 271.9M $

Stocks from 23andMe

Explore more on business

Talking Points:

  • DNA Genetic Testing For Health, Ancestry And More - 23andMe United Kingdom
  • 23andMe offers DNA testing with the most comprehensive ancestry breakdown, personalized health insights and more.
  • Your DNA has a lot to say about your health, traits and ancestry. For help, tweet us @23andMesupport.
  • Our mission is to help people access, understand and benefit from the human genome. | 23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company's mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as ...
  • 23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Learn more about talking points

In literature

There is no book written about 23andMe in the database

Related

Connected or similar:

Details

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter

This content can be used under the CC BY 4.0 license